Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder: the baclophone cohort study protocol

Autor: Benjamin Rolland, Marine Auffret, Céline Masquelier, Maryse Lapeyre-Mestre, Isabelle Grit, Marie Drelon, Alain Dervaux, François Vabret, Malek Dib, Julien Labreuche, Alain Duhamel, Aomar Kemkem, Olivier Guillin, Olivier Cottencin, Sophie Gautier, Louise Carton, Nicolas Cabé, Régis Bordet, Sylvie Deheul, Alexandre Baguet, Renaud Jardri

Publikováno v: Expert Opinion on Drug Safety
Expert Opinion on Drug Safety, Informa Healthcare, 2016, Expert opinion on drug safety, 16 (2), pp.125-132. ⟨10.1080/14740338.2017.1270939⟩
Expert Opinion on Drug Safety, 2016, Expert opinion on drug safety, 16 (2), pp.125-132. ⟨10.1080/14740338.2017.1270939⟩

International audience; BACKGROUND: In France, baclofen is frequently used off-label for alcohol use disorder (AUD). Baclofen has been associated with diverse adverse events (AEs), but the causality of these AEs has never been properly assessed.METHO

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9906fcb9800acd2caeacf02c7de6bce
https://hal.univ-lille.fr/hal-02534550